reports
Progress on ABN AMRO share buyback programme 19 April – 25 April 2024
Progress on ABN AMRO share buyback programme 19 April – 25 April 2024 Progress on ABN AMRO share buyback programme 19 April – 25 April 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 19 April 2024 up to and including 25 April 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.72 for a total amount of €47,170,980. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase tra...
Progress on ABN AMRO share buyback programme 12 April – 18 April 2024
Progress on ABN AMRO share buyback programme 12 April – 18 April 2024 Progress on ABN AMRO share buyback programme 12 April – 18 April 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 12 April 2024 up to and including 18 April 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.74 for a total amount of €47,215,740.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions an...
Progress on ABN AMRO share buyback programme 5 April – 11 April 2024
Progress on ABN AMRO share buyback programme 5 April – 11 April 2024 Progress on ABN AMRO share buyback programme 5 April – 11 April 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 5 April 2024 up to and including 11 April 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €16.37 for a total amount of €49,112,760. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and week...
- Guy Sips
- Hilde Van Boxstael
- Thomas Vranken
- Wim Lewi
- Guy Sips
Agfa Undergoing a life changing transformation journey
Model update after FY23 as Agfa is undergoing a life-changing transformation to become a future-proof, profitable company with a mission. Agfa aims a) to improve patients' lives by contributing to the quality of diagnosis; b) participate in the development of green hydrogen to help decarbonise the world; c) develop innovative digital printing solutions that reduce the environmental footprint.
Progress on ABN AMRO share buyback programme 29 March – 4 April 2024
Progress on ABN AMRO share buyback programme 29 March – 4 April 2024 Progress on ABN AMRO share buyback programme 29 March – 4 April 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 29 March 2024 up to and including 4 April 2024 a total of 1,800,000 shares and depositary receipts were repurchased at an average price of €16.14 for a total amount of €29,053,980.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and w...
- David Seynnaeve
- PhD
Hyloris Pharma - Post-FY23 model revisions
*HYL's recent FY23 publication indicated 1/ a 44% increase YoY in its product revenue with significant further ramp-up expected in ‘24 with at least doubling of product revenue (mainly driven by commercial rollout of Maxigesic IV in the USA) and 2/ further increase in R&D expenses in ‘24.*As a result thereof and based on more in-depth analysis of the value proposition of each asset, we 1/ finetuned revenue & cost estimates for the coming years and 2/ aligned the clinical and commercial stra...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update April 2024: Adding TINC
We continue our KBC Securities Dynamic Top Pick List with a 50/50 cyclical/defensive selection, but with a focus on value stocks that have been left behind. Defensive segment like holdings are overweight. However, in the Benelux we have a selection of cyclical industrials at cheap valuations that have often underperformed the market. We favour Benelux value stocks as even a mild recession typically hits growth stocks proportionally harder. We notice that some stocks have been hit hard by minor s...
BEKB BEKAERT SA
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
EVS EVS BROADCAST EQUIPMENT SA
SOLB SOLVAY SA
DIE D'IETEREN SA
SOF SOFINA SA
GIMB GIMV NV
VAN VAN DE VELDE S.A.
IBAB ION BEAM APPLICATIONS SA
ACKB ACKERMANS & VAN HAAREN NV
ARCAD ARCADIS NV
TUB FINANCIERE DE TUBIZE S.A.
CPINV CARE PROPERTY INVEST SA
TWEKA TKH GROUP N.V. CERT
TINC TINC COMM. VA
SHUR SHURGARD SELF STORAGE LIMITED
SYENS SYENSQO
Progress on ABN AMRO share buyback programme 22 – 28 March 2024
Progress on ABN AMRO share buyback programme 22 – 28 March 2024 Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly rep...
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Thomas Vranken
- Wim Hoste
- Jacob Mekhael
Hyloris Moving ahead with clinical and regulatory progress
Hyloris has made clinical and regulatory progress in the last 12 months, most notably the FDA approval for Combogesic IV in the US. In addition, the company has made a number of new product announcements expanding its pipeline to 18 reformulated and repurposed products, and 3 generics. Hyloris continues to aim for 30 products by 2025, which means we should expect an eventful period in terms of new product announcements. We summarise Hyloris' progress, and revamp our model to incorporate the new ...
Progress on ABN AMRO share buyback programme 15 – 21 March 2024
Progress on ABN AMRO share buyback programme 15 – 21 March 2024 Progress on ABN AMRO share buyback programme 15 – 21 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 15 March 2024 up to and including 21 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.32 for a total amount of €45,945,300.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly rep...
- Suvi Platerink Kosonen
Bank on it/Where to hide from property woes?
Commercial real estate remains one of the key risk areas for European banks in our view. We take a look at where to hide from potential further CRE worries in the banking sector and see that for many of the names with more limited CRE exposures this is already reflected in relatively tighter spread levels.
Progress on ABN AMRO share buyback programme 8 – 14 March 2024
Progress on ABN AMRO share buyback programme 8 – 14 March 2024 Progress on ABN AMRO share buyback programme 8 – 14 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 8 March 2024 up to and including 14 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.01 for a total amount of €45,037,380.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly report...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Hyloris FIRST LOOK: FY23 results show pipeline progress, eventful year...
Hyloris reported FY23 results showcasing the company's pipeline progress and highlighting an eventful year ahead. The company had € 30.2m in cash, which it expects to provide a runway of 18-24 months. On the pipeline front, timelines were more or less reiterated and we most look forward to the results from the pivotal study for Dofetilide IV in atrial fibrillation expected in 3Q24, which could support an NDA submission soon after. In addition to the existing pipeline (18 reformulated/repurposed ...
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook Hyloris Reports Full Year Results for 2023 & Provides Business Outlook Total revenue and other income amounted to €4.4 millionStronger growth expected in 2024 of both sales and gross margin, mainly fueled by the recent launch in the U.S. of Maxigesic® IV and Podofilox gel, the global roll out of Maxigesic IV® and commercial dealsIncreased operating R&D expenses while net operating cash outflow remained stable versus 2022Significant R&D progress including clinical and regulatory achievements with multiple NDA submissions...
Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives
Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives Le total des produits et autres revenus atteint 4,4 millions d’eurosForte croissance du chiffre d’affaires et de la marge bute attendue en 2024, principalement alimentée par le lancement récent aux États-Unis de Maxigesic® IV et du gel Podofilox, le déploiement mondial de Maxigesic IV® et des accords commerciauxAugmentation des dépenses opérationnelles de R&D mais sorties de trésorerie nettes stables par rapport à 2022Progrès significatifs en matière ...
Communication at the request of the FSMA on the transactions with Qlin...
Communication at the request of the FSMA on the transactions with Qliniq Communication at the request of the FSMA on the transactions with Qliniq Revision of 2022 and half-year of 2023 (HY 2023) financial statements following a correction of a non-cash error in the accounting treatment of the transactions with Qliniq announced on 20 January 2023HY-088 and HY-038 considered as a non-monetary exchange under IAS 38.45 in 2023No impact on the cash flow and cash position Liège, Belgium – 14 March 2023 – 07:00AM CET – Regulated Information – Inside informaition - Hyloris Pharmaceutica...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.